<DOC>
	<DOC>NCT03050398</DOC>
	<brief_summary>This study will allow for the collection of tumor tissue samples to better understand relevant mutations and the mechanisms responsible for resistance to treatment.</brief_summary>
	<brief_title>A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib</brief_title>
	<detailed_description>This protocol is a sub-protocol of an interventional study. Because the main study is interventional, this study was approved by FDA as an interventional study. It cannot stand alone without the parent study. The sites will receive diagnostic information for all patients that come on study.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Written informed consent must be obtained prior to any baseline/screening procedures. Patients eligible for this companion sample collection protocol sample collection protocol must meet all inclusion in CLEE011A2404. Patients eligible for this companion sample collection protocol must not meet any of the exclusion criteria in the CLEE011A2404 study, in addition to the following: Patients without either fresh or archival tumor tissue accessible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>ribociclib</keyword>
	<keyword>letrozole</keyword>
	<keyword>femara</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>Phase IIIb</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Premenopausal</keyword>
	<keyword>Men</keyword>
</DOC>